未来治疗精神分裂症认知缺陷和阴性症状的前景。
Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.
机构信息
Nathan Kline Institute for Psychiatric Research, New York University School of Medicine, 140 Old Orangeburg Road, Orangeburg, NY, 10962, USA.
出版信息
World Psychiatry. 2013 Jun;12(2):99-107. doi: 10.1002/wps.20026.
Abstract
Drug discovery based on classic models for cognitive impairment and negative symptoms of schizophrenia have met with only modest success. Because cognitive impairment and negative symptoms may result from disruptions in neurodevelopment, more complex developmental models that integrate environmental and genetic risk factors are needed. In addition, it has become clear that biochemical pathways involved in schizophrenia form complex, interconnected networks. Points at which risk factors converge, such as brain-derived neurotrophic factor (BDNF) and protein kinase B (AKT), and from which processes involved in neuroplasticity diverge, are of particular interest for pharmacologic interventions. This paper reviews elements of neurodevelopmental models for cognitive deficits and negative symptoms of schizophrenia with the aim of identifying potential targets for interventions.
摘要
基于经典模型的认知障碍和精神分裂症阴性症状的药物发现仅取得了适度的成功。由于认知障碍和阴性症状可能是由于神经发育紊乱引起的，因此需要更复杂的整合环境和遗传风险因素的发育模型。此外，已经清楚的是，涉及精神分裂症的生化途径形成复杂的、相互关联的网络。风险因素汇聚的点，如脑源性神经营养因子 (BDNF) 和蛋白激酶 B (AKT)，以及涉及神经可塑性的过程分歧的点，对于药物干预特别有意义。本文综述了精神分裂症认知缺陷和阴性症状的神经发育模型的要素，旨在确定干预的潜在靶点。
相似文献
1
Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.未来治疗精神分裂症认知缺陷和阴性症状的前景。
World Psychiatry. 2013 Jun;12(2):99-107. doi: 10.1002/wps.20026.
2
BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory.脑源性神经营养因子与精神分裂症：从神经发育到神经元可塑性、学习和记忆。
Front Psychiatry. 2013 Jun 17;4:45. doi: 10.3389/fpsyt.2013.00045. eCollection 2013.
3
Exercise Induced Neuroplasticity to Enhance Therapeutic Outcomes of Cognitive Remediation in Schizophrenia: Analyzing the Role of Brai nderived Neurotrophic Factor.运动诱导的神经可塑性增强精神分裂症认知矫正的治疗效果：分析脑源性神经营养因子的作用。
CNS Neurol Disord Drug Targets. 2017;16(6):638-651. doi: 10.2174/1871527315666161223142918.
4
Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers.精神分裂症患者和健康志愿者中脑源性神经营养因子Val66Met基因多态性的认知及磁共振成像脑形态学相关性
Arch Gen Psychiatry. 2006 Jul;63(7):731-40. doi: 10.1001/archpsyc.63.7.731.
5
Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naïve patients with schizophrenia.BDNF Val66Met 多态性与抗精神病药初治精神分裂症患者认知功能的关系。
J Mol Neurosci. 2012 Jul;47(3):505-10. doi: 10.1007/s12031-012-9750-4. Epub 2012 Apr 3.
6
Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia.脑源性神经营养因子水平低与慢性精神分裂症患者的认知障碍有关。
Psychopharmacology (Berl). 2012 Jul;222(2):277-84. doi: 10.1007/s00213-012-2643-y. Epub 2012 Jan 26.
7
Decreased Peripheral BDNF Levels and Cognitive Impairment in Late-Life Schizophrenia.老年精神分裂症患者外周脑源性神经营养因子水平降低与认知障碍
Front Psychiatry. 2021 Jun 22;12:641278. doi: 10.3389/fpsyt.2021.641278. eCollection 2021.
8
Cognitive impairment in first-episode drug-naïve patients with schizophrenia: Relationships with serum concentrations of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor.首发未用药精神分裂症患者的认知障碍：与脑源性神经营养因子和胶质细胞源性神经营养因子血清浓度的关系。
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 2;76:163-168. doi: 10.1016/j.pnpbp.2017.03.013. Epub 2017 Mar 22.
9
Brain derived neurotrophic factor Val66Met polymorphism and psychotic symptoms in Alzheimer's disease.脑源性神经营养因子 Val66Met 多态性与阿尔茨海默病的精神病症状。
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):356-62. doi: 10.1016/j.pnpbp.2010.10.020. Epub 2010 Oct 31.
10
Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond.发育基因与调控蛋白、精神分裂症谱系精神病认知障碍的领域及其对抗精神病药物研发的意义：以失调结合蛋白-1亚型为例及其他
Front Pharmacol. 2020 Jan 29;10:1638. doi: 10.3389/fphar.2019.01638. eCollection 2019.
引用本文的文献
1
Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia.NMDA 受体功能障碍在精神分裂症病理生理学和/或治疗抵抗性精神分裂症发病机制中的作用。
Biomolecules. 2024 Sep 6;14(9):1128. doi: 10.3390/biom14091128.
2
Disturbed Oligodendroglial Maturation Causes Cognitive Dysfunction in Schizophrenia: A New Hypothesis.精神分裂症中少突胶质细胞成熟障碍导致认知功能障碍：一个新假说。
Schizophr Bull. 2023 Nov 29;49(6):1614-1624. doi: 10.1093/schbul/sbad065.
3
Brain Derived Neurotrophic Factor and Cognitive Dysfunction in the Schizophrenia-Bipolar Spectrum: A Systematic Review and Meta-Analysis.精神分裂症-双相谱系障碍中的脑源性神经营养因子与认知功能障碍：一项系统评价与荟萃分析
Front Psychiatry. 2022 May 24;13:827322. doi: 10.3389/fpsyt.2022.827322. eCollection 2022.
4
Elevated activity of superoxide dismutase in male late-life schizophrenia and its correlation with clinical symptoms and cognitive deficits.男性迟发性精神分裂症中超氧化物歧化酶活性升高及其与临床症状和认知功能障碍的相关性。
BMC Psychiatry. 2021 Dec 4;21(1):606. doi: 10.1186/s12888-021-03604-5.
5
BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review.脑源性神经营养因子作为精神分裂症/精神病认知功能的生物标志物：最新综述
Front Psychiatry. 2021 Jun 16;12:662407. doi: 10.3389/fpsyt.2021.662407. eCollection 2021.
6
Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study.撒丁岛精神病患者脑源性神经营养因子的纵向评估（LABSP）：一项前瞻性观察性研究方案
BMJ Open. 2017 May 25;7(5):e014938. doi: 10.1136/bmjopen-2016-014938.
7
The Efficacy of Non-Pharmacological Interventions on Brain-Derived Neurotrophic Factor in Schizophrenia: A Systematic Review and Meta-Analysis.非药物干预对精神分裂症患者脑源性神经营养因子的疗效：一项系统评价与荟萃分析
Int J Mol Sci. 2016 Oct 24;17(10):1766. doi: 10.3390/ijms17101766.
8
The Impact of Aerobic Exercise on Brain-Derived Neurotrophic Factor and Neurocognition in Individuals With Schizophrenia: A Single-Blind, Randomized Clinical Trial.有氧运动对精神分裂症患者脑源性神经营养因子和神经认知的影响：一项单盲随机临床试验
Schizophr Bull. 2015 Jul;41(4):859-68. doi: 10.1093/schbul/sbv022. Epub 2015 Mar 23.
9
A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation.对精神病中促认知药物靶点的批判性综述：聚焦于髓鞘形成和炎症
Front Psychiatry. 2014 Feb 4;5:11. doi: 10.3389/fpsyt.2014.00011. eCollection 2014.
10
Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.精神分裂症患者神经认知缺陷的心理药理学治疗：新旧靶点综述
CNS Drugs. 2014 Apr;28(4):301-18. doi: 10.1007/s40263-014-0146-6.
本文引用的文献
1
Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia.叶酸联合维生素 B12 补充治疗精神分裂症的多中心随机对照研究。
JAMA Psychiatry. 2013 May;70(5):481-9. doi: 10.1001/jamapsychiatry.2013.900.
2
A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples.一项使用死后脑组织样本对精神分裂症进行的系统水平转录组分析。
Arch Gen Psychiatry. 2012 Dec;69(12):1205-13. doi: 10.1001/archgenpsychiatry.2012.704.
3
Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users.确认 AKT1(rs2494732) 基因型影响使用大麻者患精神病的风险。
Biol Psychiatry. 2012 Nov 15;72(10):811-6. doi: 10.1016/j.biopsych.2012.06.020. Epub 2012 Jul 24.
4
Prenatal activation of Toll-like receptors-3 by administration of the viral mimetic poly(I:C) changes synaptic proteins, N-methyl-D-aspartate receptors and neurogenesis markers in offspring.产前给予病毒模拟物聚肌苷酸-聚胞苷酸激活 Toll 样受体 3，可改变子代的突触蛋白、N-甲基-D-天冬氨酸受体和神经发生标志物。
Mol Brain. 2012 Jun 9;5:22. doi: 10.1186/1756-6606-5-22.
5
Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial.ω-3 补充剂可降低健康中年和老年人的炎症：一项随机对照试验。
Brain Behav Immun. 2012 Aug;26(6):988-95. doi: 10.1016/j.bbi.2012.05.011. Epub 2012 May 26.
6
Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment.米诺环素对早期精神分裂症的阴性症状有益：一项在标准治疗基础上对患者进行的随机、双盲、安慰剂对照临床试验。
J Psychopharmacol. 2012 Sep;26(9):1185-93. doi: 10.1177/0269881112444941. Epub 2012 Apr 23.
7
Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes.认知障碍与首发精神病发作中的氧化应激和趋化因子水平有关。
Schizophr Res. 2012 May;137(1-3):66-72. doi: 10.1016/j.schres.2012.03.004. Epub 2012 Mar 22.
8
Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial.谷胱甘肽前体 N-乙酰半胱氨酸调节精神分裂症患者的脑电图同步：一项双盲、随机、安慰剂对照试验。
PLoS One. 2012;7(2):e29341. doi: 10.1371/journal.pone.0029341. Epub 2012 Feb 22.
9
D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia.D-环丝氨酸：精神分裂症学习和神经可塑性中的作用不断演变。
Schizophr Bull. 2012 Sep;38(5):936-41. doi: 10.1093/schbul/sbs012. Epub 2012 Feb 23.
10
Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies.二十碳五烯酸干预精神分裂症的随机、安慰剂对照研究的荟萃分析。
J Clin Psychopharmacol. 2012 Apr;32(2):179-85. doi: 10.1097/JCP.0b013e318248b7bb.
Zotero 插件